DMAC
NASDAQ
US
DiaMedica Therapeutics Inc. - Common Stock
$6.48
▲ +$0.06
(+0.93%)
Vol 131K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$414.5M
ROE
-83.2%
D/E
0.03
Beta
1.11
52W
$3–$10
Wall Street Consensus
11 analysts · Apr 20262
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
CADL
Candel Therapeutics Inc
$310.2M
IVVD
Invivyd Inc
$684.5M
IMRX
Immuneering Corp
$424.9M
PBYI
Puma Biotechnology Inc
P/E 8.1
$299.8M
CABA
Cabaletta Bio Inc
$210.8M
XOMA
Xoma Royalty Corp
P/E 15.2
$329.3M
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
Earnings
Beat rate: 60.0%
Next Report
May 11, 2026
EPS Estimate: $-0.19
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.19 | — | — |
| Dec 2025 | $-0.18 | $-0.17 | +$0.01 |
| Sep 2025 | $-0.16 | $-0.17 | $-0.01 |
| Jun 2025 | $-0.19 | $-0.18 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$6.3M | -$7.9M | -$7.7M | -$7.7M | -$8.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -79.0% | -61.4% | -79.0% | -79.0% | -79.0% | -83.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | 0.03 |
| Current Ratio | 7.55 | 8.02 | 7.55 | 7.55 | 7.55 | 10.67 |
Key Ratios
ROA (TTM)
-73.5%
P/B
5.7
EPS (TTM)
$-0.72
CF/Share
$-0.61
52W High
$10.42
52W Low
$3.19
$3.19
52-Week Range
$10.42
Financial Health
Free Cash Flow
-$6.6M
Net Debt
-$3.1M
Cash
$3.3M
Total Debt
$266K
As of Sep 30, 2025
How does DMAC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DMAC valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
5.7
▲
132%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DMAC profitability vs Biotechnology peers
ROE
-83.2%
▼
24%
below
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-73.5%
▼
57%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
DMAC financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
10.7
▲
140%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.1
▲
15%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
DMAC fundamentals radar
DMAC
Peer median
Industry
DMAC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DMAC vs peers: key metrics
Top Holders
Top 5: 12.16%Cooperman, Leon G.
3.88%
$13.7M
Blackrock Inc.
3.65%
$12.9M
Paragon Associates & Parago…
1.68%
$5.9M
Millennium Management Llc
1.48%
$5.2M
Geode Capital Management, L…
1.47%
$5.2M
As of Dec 31, 2025
Latest News
No related news yet